Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Change in Account Payables (2020 - 2025)

Roivant Sciences (ROIV) has disclosed Change in Account Payables for 6 consecutive years, with -$4.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Account Payables rose 77.85% year-over-year to -$4.0 million, compared with a TTM value of -$30.7 million through Dec 2025, up 10.28%, and an annual FY2025 reading of -$18.2 million, down 180.09% over the prior year.
  • Change in Account Payables was -$4.0 million for Q4 2025 at Roivant Sciences, down from $3.0 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $62.9 million in Q3 2021 and bottomed at -$25.3 million in Q2 2024.
  • Average Change in Account Payables over 5 years is $2.9 million, with a median of $1.8 million recorded in 2023.
  • Peak annual rise in Change in Account Payables hit 501.0% in 2024, while the deepest fall reached 1101.84% in 2024.
  • Year by year, Change in Account Payables stood at $3.7 million in 2021, then surged by 278.28% to $14.0 million in 2022, then crashed by 87.14% to $1.8 million in 2023, then plummeted by 1101.84% to -$18.0 million in 2024, then surged by 77.85% to -$4.0 million in 2025.
  • Business Quant data shows Change in Account Payables for ROIV at -$4.0 million in Q4 2025, $3.0 million in Q3 2025, and -$11.7 million in Q2 2025.